09.04.18
Probiodrug AG announced that Dr. Michael Schaeffer has been appointed to the position of executive vice president of Business and Strategy, effective August 2018.
Dr. Schaeffer brings more than 15 years of experience across pharma and biotech in strategic business development, scientific project and alliance management to Probiodrug.
Chief executive officer of Probiodrug, Dr. Ulrich Dauer, said, “We are very pleased Michael has joined our team. His entrepreneurial skill sets and extensive experience in strategic business development for neurology projects across all stages of drug development will be invaluable in defining Probiodrug's business strategies. Additionally, he brings significant experience in advancing innovations in R&D alliance and CRO partnership management on a global scale. Together we look forward to tackling the next developmental stages of our lead candidate PQ912 as we prepare for our upcoming global Phase 2b studies.”
Prior to joining Probiodrug, Dr. Schaeffer was the founder and managing director of biotech companies, CRELUX GmbH and SiREEN AG.
“I was looking for an exciting business development role at a company that develops innovative drugs based on outstanding science and for indications with an extremely high medical need. Probiodrug exactly matches these requirements – I look forward to making a significant contribution as we are advancing our drug discovery programs” Dr. Michael Schaeffer said.
Chief executive officer of Probiodrug, Dr. Ulrich Dauer, said, “We are very pleased Michael has joined our team. His entrepreneurial skill sets and extensive experience in strategic business development for neurology projects across all stages of drug development will be invaluable in defining Probiodrug's business strategies. Additionally, he brings significant experience in advancing innovations in R&D alliance and CRO partnership management on a global scale. Together we look forward to tackling the next developmental stages of our lead candidate PQ912 as we prepare for our upcoming global Phase 2b studies.”
Prior to joining Probiodrug, Dr. Schaeffer was the founder and managing director of biotech companies, CRELUX GmbH and SiREEN AG.
“I was looking for an exciting business development role at a company that develops innovative drugs based on outstanding science and for indications with an extremely high medical need. Probiodrug exactly matches these requirements – I look forward to making a significant contribution as we are advancing our drug discovery programs” Dr. Michael Schaeffer said.